Balyasny Asset Management
NRXP icon

Balyasny Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Balyasny Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.66M Buy
+893,864
New +$2.95M ﹤0.01% 1523

Other funds holding NRXP

BGI
B Group Inc Dallas, Texas $213M AUM 96.05% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Balyasny Asset Management's NRXP Position: Q2 2026 in Review

Balyasny Asset Management opened a new position in NRX Pharmaceuticals (NRXP) in Q2 2026: 893,864 shares worth $3.66M. The stake represents ﹤0.01% of the portfolio and ranks #1523 among its holdings.

46 funds tracked by Wall St. Rank hold NRXP as of Q2 2026.

  • Balyasny Asset Management held 893,864 shares of NRX Pharmaceuticals worth $3.66M as of Q2 2026.
  • NRX Pharmaceuticals was a new Balyasny Asset Management position in Q2 2026.
  • NRX Pharmaceuticals made up ﹤0.01% of Balyasny Asset Management's portfolio in Q2 2026, its #1523 holding.
  • 46 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.